153 related articles for article (PubMed ID: 28671793)
1. [Gliptin-gliflozin combination for treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Scheen AJ
Clin Pharmacokinet; 2017 Jul; 56(7):703-718. PubMed ID: 28039605
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
5. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK
Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
[TBL] [Abstract][Full Text] [Related]
7. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Gallwitz B
Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Rizos CV; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
[TBL] [Abstract][Full Text] [Related]
11. The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies.
Molina-Vega M; Muñoz-Garach A; Fernández-García JC; Tinahones FJ
Expert Opin Drug Saf; 2018 Aug; 17(8):815-824. PubMed ID: 29975558
[TBL] [Abstract][Full Text] [Related]
12. An update on DPP-4 inhibitors in the management of type 2 diabetes.
Cahn A; Cernea S; Raz I
Expert Opin Emerg Drugs; 2016 Dec; 21(4):409-419. PubMed ID: 27809608
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Yassin SA; Aroda VR
Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
Barnett AH; Charbonnel B; Moses RG; Kalra S
Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Dey J
Postgrad Med; 2017 May; 129(4):409-420. PubMed ID: 28322073
[TBL] [Abstract][Full Text] [Related]
16. [How I manage a patient with type 2 diabetes not well controlled with a metformin plus gliptin combination].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):443-450. PubMed ID: 31486312
[TBL] [Abstract][Full Text] [Related]
17. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X; Hu J
Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
